Yansen Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yansen Bai has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Wanlu Liu
School of Public Health, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou 511436, China
7 shared publicationsXinyu Zhu
School of Public Health, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou 511436, China
7 shared publicationsMengya Xu
School of Public Health, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou 511436, China
6 shared publicationsBaihao Lin
School of Public Health, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou 511436, China
5 shared publicationsYuyu Zheng
School of Public Health, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou 511436, China
5 shared publicationsGuoliang Li
Chief Physician, Department of Toxicology, Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, China
2 shared publications
Latest Publications
- 6 May 2026
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 214, 116127
Cosmetic exposure and hepatic steatosis: Investigating the role of metals and adipokines
- 6 May 2026
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 214, 116127
Cosmetic exposure and hepatic steatosis: Investigating the role of metals and adipokines
- 15 March 2026
- Published by Elsevier in Environmental Research
- Vol. 298, 124293
PFAS and adipokines: Decoding their roles in the risk of breast nodules and breast cancer
- 15 March 2026
- Published by Elsevier in Environmental Research
- Vol. 298, 124293
PFAS and adipokines: Decoding their roles in the risk of breast nodules and breast cancer
- Open Access
- 4 August 2025
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 37 (1) , 1-15
Unveiling the metabolic roles: how lead exposure elevates uric acid levels
- 4 August 2025
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 37 (1) , 1-15
Open AccessUnveiling the metabolic roles: how lead exposure elevates uric acid levels
- Open Access
- 23 July 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 302, 118733
Effects of lithium nickel manganese cobalt oxide exposure on biological age acceleration: Insights from metabolomics
- 23 July 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 302, 118733
Open AccessEffects of lithium nickel manganese cobalt oxide exposure on biological age acceleration: Insights from metabolomics
- Open Access
- 22 March 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 79, 607-618
From repellent to risk: DEET’s adverse effects on hormones and bone health in kids
- 22 March 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 79, 607-618
Open AccessFrom repellent to risk: DEET’s adverse effects on hormones and bone health in kids
- Open Access
- 9 December 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 289, 117496
Associations of co-exposure to polycyclic aromatic hydrocarbons and vitamin D with early lung dysfunction: Mediating roles of metabolic score-visceral adiposity index
- 9 December 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 289, 117496
Open AccessAssociations of co-exposure to polycyclic aromatic hydrocarbons and vitamin D with early lung dysfunction: Mediating roles of metabolic score-visceral adiposity index
- Top Cited PapersOpen Access
- 30 August 2024
- Published by Elsevier in Redox Biology
- Vol. 76, 103334
Associations of dietary inflammation index and composite dietary antioxidant index with preserved ratio impaired spirometry in US adults and the mediating roles of triglyceride-glucose index: NHANES 2007–2012
- 30 August 2024
- Published by Elsevier in Redox Biology
- Vol. 76, 103334
Top Cited PapersOpen AccessAssociations of dietary inflammation index and composite dietary antioxidant index with preserved ratio impaired spirometry in US adults and the mediating roles of triglyceride-glucose index: NHANES 2007–2012
- Open Access
- 1 January 2024
- Published by Wiley in Indoor Air
- Vol. 2024 (1)
Shared Risk Volatile Organic Compounds Among Chronic Respiratory Diseases: Mediation Effects of System Inflammation
Background: Volatile organic compounds (VOCs) are indoor and outdoor air pollution, but the VOCs that were shared across chronic respiratory diseases (CRDs) remained unknown. Meanwhile, the mediating roles of system inflammation need to be further explored.Methods: This study included 9114 adults based on the National Health and Nutrition Examination Survey (NHANES) 2005–2006 and 2011–2018. Internal exposure levels of 14 urinary metabolites of VOC (mVOCs), blood cell count–derived inflammatory biomarkers, and prevalent CRDs, including asthma, chronic bronchitis, and emphysema, were assessed and collected. Associations of single‐ and multiple‐mVOCs with CRDs were assessed by using logistic regression and quantile‐based g‐computation (QGcomp) methods to select the key and shared mVOCs among CRDs. Mediation effects of system inflammation on mVOC‐CRD associations were further evaluated by causal mediation analysis.Results: Increased levels of total 14 mVOCs were associated with increased risk of chronic bronchitis (OR = 1.62, 95% CI: 1.37–1.91), emphysema (OR = 1.73, 95% CI: 1.27–2.35), and both conditions combined (defined as chronic obstructive pulmonary disease, COPD) (OR = 1.61, 95% CI: 1.37–1.88), but not for asthma (OR = 1.07, 95% CI: 0.94–1.21). In both single‐ and multiple‐mVOC exposure models, 8 key mVOCs were COPD associated, including 6 mVOCs (34MHA, AMCC, CEMA, DHBMA, 3HPMA, and MHBMA3) and 5 mVOCs (34MHA, CYMA, 3HPMA, MA, and MHBMA3) that were associated with increased risk of chronic bronchitis and emphysema, respectively. Particularly, 34MHA, 3HPMA, and MHBMA3 were shared risk factors across chronic bronchitis, emphysema, and COPD. Neutrophils mediated the associations of three shared mVOCs with chronic bronchitis (by 5.20%, 7.80%, 6.30%), emphysema (by 6.90%, 9.30%, 9.70%), and COPD (by 5.80%, 8.90%, 7.70%).Conclusions: These findings provide valuable insights into the shared risk mVOCs and mediating roles of neutrophils involved in the pathogenesis of CRDs, which can be useful in developing more effective prevention and intervention strategies for CRDs.
- 1 January 2024
- Published by Wiley in Indoor Air
- Vol. 2024 (1)
Open AccessShared Risk Volatile Organic Compounds Among Chronic Respiratory Diseases: Mediation Effects of System Inflammation
Background: Volatile organic compounds (VOCs) are indoor and outdoor air pollution, but the VOCs that were shared across chronic respiratory diseases (CRDs) remained unknown. Meanwhile, the mediating roles of system inflammation need to be further explored.Methods: This study included 9114 adults based on the National Health and Nutrition Examination Survey (NHANES) 2005–2006 and 2011–2018. Internal exposure levels of 14 urinary metabolites of VOC (mVOCs), blood cell count–derived inflammatory biomarkers, and prevalent CRDs, including asthma, chronic bronchitis, and emphysema, were assessed and collected. Associations of single‐ and multiple‐mVOCs with CRDs were assessed by using logistic regression and quantile‐based g‐computation (QGcomp) methods to select the key and shared mVOCs among CRDs. Mediation effects of system inflammation on mVOC‐CRD associations were further evaluated by causal mediation analysis.Results: Increased levels of total 14 mVOCs were associated with increased risk of chronic bronchitis (OR = 1.62, 95% CI: 1.37–1.91), emphysema (OR = 1.73, 95% CI: 1.27–2.35), and both conditions combined (defined as chronic obstructive pulmonary disease, COPD) (OR = 1.61, 95% CI: 1.37–1.88), but not for asthma (OR = 1.07, 95% CI: 0.94–1.21). In both single‐ and multiple‐mVOC exposure models, 8 key mVOCs were COPD associated, including 6 mVOCs (34MHA, AMCC, CEMA, DHBMA, 3HPMA, and MHBMA3) and 5 mVOCs (34MHA, CYMA, 3HPMA, MA, and MHBMA3) that were associated with increased risk of chronic bronchitis and emphysema, respectively. Particularly, 34MHA, 3HPMA, and MHBMA3 were shared risk factors across chronic bronchitis, emphysema, and COPD. Neutrophils mediated the associations of three shared mVOCs with chronic bronchitis (by 5.20%, 7.80%, 6.30%), emphysema (by 6.90%, 9.30%, 9.70%), and COPD (by 5.80%, 8.90%, 7.70%).Conclusions: These findings provide valuable insights into the shared risk mVOCs and mediating roles of neutrophils involved in the pathogenesis of CRDs, which can be useful in developing more effective prevention and intervention strategies for CRDs.
- 1 October 2023
- Published by Elsevier in Science of The Total Environment
- Vol. 906, 167506
Essential metals modified the effects of polycyclic aromatic hydrocarbons on the metabolic syndrome: Mediation effects of miRNA
- 1 October 2023
- Published by Elsevier in Science of The Total Environment
- Vol. 906, 167506
Essential metals modified the effects of polycyclic aromatic hydrocarbons on the metabolic syndrome: Mediation effects of miRNA
- Open Access
- 3 March 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-8
A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients. We conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including 140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401 in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with overall survival of these patients was further analyzed. It was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However, the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma. The rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup. However, these results need to be validated in larger populations of lung cancer and the biological function of this variant still warrants further investigation.
- 3 March 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 1-8
Open AccessA genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis
Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients. We conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including 140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401 in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with overall survival of these patients was further analyzed. It was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However, the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma. The rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup. However, these results need to be validated in larger populations of lung cancer and the biological function of this variant still warrants further investigation.